ASPIRE Phase 3 Failure Leaves Angelman Syndrome Without a Cognitive Therapy and Ultragenyx Pivoting Away

Ultragenyx's Aspire Study for Angelman Syndrome Misses Endpoints

Ultragenyx Pharmaceutical Inc. announced that its Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome did not meet its primary endpoint of change from Baseline in Bayley-4 cognitive raw score, nor its key secondary endpoint of net response in Multidomain Responder Index (MDRI). The safety profile observed was consistent with earlier phases. Following these results, Ultragenyx plans to evaluate the apazunersen program's future and implement significant expense reductions while focusing on its growing commercial business, which includes new revenue from GENGLYCOS and the potential approval of UX111, aiming for profitability in 2027.

• The Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome failed to achieve its primary endpoint, which was the change from Baseline in Bayley-4 cognitive raw score. Additionally, the key secondary endpoint, net response in the Multidomain Responder Index (MDRI), was also not met, indicating no significant efficacy difference between treated and control groups.
• Ultragenyx expressed disappointment with the Aspire results and announced plans to evaluate the apazunersen program's disposition. The company will also assess its operations to implement significant expense reductions, while reaffirming its commitment to its growing commercial business and pipeline, aiming for profitability in 2027.
• Apazunersen (GTX-102) is an investigational antisense oligonucleotide (ASO) therapy administered intrathecally. It is designed to inhibit UBE3A-AS expression to prevent silencing of the paternally inherited UBE3A gene. The drug has received multiple regulatory designations, including Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track from the FDA, and Orphan and PRIME designations from the EMA.

The Aspire Study: Design, Endpoints, and Unexpected Outcomes

Several prospective studies have evaluated clinical outcome assessments, biomarkers, and dietary interventions in Angelman syndrome (AS), collectively informing the endpoint landscape for interventional trials. The studies span a range of designs — from observational longitudinal cohorts to prospective dietary intervention trials — and employ both established and novel measurement tools.

• FREESIAS (Prospective, Longitudinal, Observational Study): Enrolled 55 individuals with AS (aged <5 years: n = 16; 5–12 years: n = 27; ≥18 years: n = 12; deletion genotype: n = 40; nondeletion genotype: n = 15) and 20 typically developing children (aged 1–12 years) across six USA sites. Participants were assessed at baseline (Clinic Visit 1), 12 months later (Clinic Visit 2), and during intermittent home visits. Endpoints included multiple clinical outcome assessments, digital health technologies, overnight 19-lead electroencephalography (EEG), and additional polysomnography (PSG) sensors. Adherence to clinical outcome assessments was 89–100% at Clinic Visit 1 and 76–91% at Clinic Visit 2. Bayley-III scores were comparable to available natural history data, and the AS EEG phenotype of excess delta-band power was consistent with prior reports.

• Low Glycemic Index Treatment (LGIT) Trial (Prospective, 4-Month Dietary Intervention): Six children (mean age 3.3 years, range 1.1–4.8) with genetically confirmed AS and refractory epilepsy were enrolled. Endpoints included daily seizure frequency (recorded via parent seizure log for a minimum of 1 month prior to and throughout the trial), EEG, and neuropsychological assessments using the Scales of Independent Behavior-Revised and the Vineland Adaptive Behavior Scales-2nd Edition, obtained at baseline and 4-month follow-up. Clinical evaluations, blood laboratory chemistries, and anthropometric measures were obtained at enrollment, month 1, and month 4. Five of six subjects exhibited >80% seizure frequency reduction; all post-trial EEG studies showed improvement, and three of four children with epileptiform activity at baseline had no discharges on follow-up EEG.

• Quantitative EEG (qEEG) Biomarker Study (Retrospective Analysis): Assessed spectral power from baseline EEG recordings in children with AS (aged 4–12 years) compared to age-matched neurotypical controls, and retrospectively analyzed data from a clinical trial evaluating minocycline (3 mg/kg/d). Endpoints included EEG spectral power (with a focus on delta power) and epileptiform events, measured at baseline, end of treatment, and following washout. Increased delta power was corroborated at baseline and during minocycline treatment; following washout, AS subjects had significantly reduced EEG spectral power and epileptiform activity.

• Overnight Sleep EEG Biomarker Study (Retrospective Analysis): Analyzed EEGs from 12 overnight sleep studies from individuals with AS, with age- and sex-matched Down syndrome and neurotypical controls. Endpoints focused on low-frequency (2–4 Hz) delta rhythms and sleep spindles across all stages of overnight sleep. Delta EEG rhythms were increased in individuals with AS during all stages of overnight sleep, but overnight sleep did not provide additional benefit over wake in detecting increased delta. Abnormal sleep spindles were not reliably detected, leading to the conclusion that periods of wakefulness are sufficient, and "perhaps ideal," to quantify delta EEG rhythms for use as AS biomarkers.

Angelman Syndrome: Genetic Basis and Apazunersen's Therapeutic Strategy

Angelman syndrome (AS) is a severe neurodevelopmental disorder rooted in the disrupted maternal expression of the UBE3A gene. Due to genomic imprinting, only neurons are affected — the paternal UBE3A allele is silenced by a paternally expressed antisense RNA transcript, UBE3A-ATS. This antisense transcript is transcribed by RNA polymerase II, is not poly-adenylated, is localized exclusively in the nucleus, and carries a half-life of approximately 4 hours. It represses paternal Ube3a in cis, meaning that loss of maternal UBE3A expression leaves neurons without functional UBE3A protein. Molecularly confirmed AS cases arise through several mechanisms: maternal microdeletion of the 15q11–q13 region (the most common cause), paternal uniparental disomy, imprinting center defects, and direct UBE3A gene mutation. In one Hong Kong cohort of 55 patients, 65.5% were caused by maternal microdeletion, 10.9% by paternal uniparental disomy, 3.6% by imprinting center defect, and 14.5% by UBE3A gene mutation.

At the synaptic and cellular level, loss of the UBE3A ubiquitin protein ligase — required for proteasomal degradation of proteins implicated in synaptic plasticity — results in elevated levels of the activity-regulated cytoskeletal-associated protein Arc/Arg3.1 in response to synaptic activity. Elevated Arc impedes the association of PSD-95 with TrkB receptors, attenuating BDNF-induced recruitment of PSD-95, PLCγ, and Grb2-associated binder 1 (Gab1) with TrkB. This results in reduced activation of the PLCγ–α-calcium/calmodulin-dependent protein kinase II (CaMKII) and PI3K-Akt pathways, while leaving the extracellular signal-regulated kinase (Erk) pathway intact. Consequently, long-term potentiation (LTP) is severely impaired in the hippocampus, and TBS-induced actin polymerization within dendritic spines — an essential event for stabilizing LTP — is deficient. These synaptic deficits translate into profound impairments in long-term memory encoding.

Beyond synaptic plasticity, AS is characterized by region-specific deficits in GABAergic inhibitory tone. Tonic inhibition, mediated by extrasynaptic GABA-A receptors, is reduced in cortical layer 5 and hippocampal CA1 pyramidal neurons but preserved in thalamic relay neurons. This reduction correlates with elevated GAT1 expression in the cortex and hippocampus but not the thalamus. The resulting excitatory/inhibitory (E/I) imbalance is thought to underlie the EEG abnormalities and heightened seizure susceptibility characteristic of AS. Separately, disruption of mTOR signaling, mitochondrial integrity, and BDNF/TrkB function signaling have also been identified as molecular alterations associated with the loss of UBE3A, further contributing to the synaptic dysfunction and cognitive impairment that define the disorder's progression.

Angelman Syndrome Setback: Redefining Rare Disease R&D

The recent announcement regarding the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome (AS) marks a sobering moment for the rare disease community and the pharmaceutical industry. Angelman syndrome, a severe neurodevelopmental disorder stemming from the loss of functional UBE3A gene expression, presents profound challenges, including developmental delay, intellectual disability, and absent speech. Apazunersen, an antisense oligonucleotide (ASO) therapy, represented a leading-edge approach to address the genetic root cause, offering hope for a disease-modifying treatment where only symptomatic management currently exists.

The failure of apazunersen to meet its primary endpoint, the Bayley-4 cognitive raw score, and its key secondary endpoint, the Multidomain Responder Index (MDRI), underscores the immense complexities inherent in developing therapies for such intricate neurological conditions. This outcome highlights several critical challenges:

• Endpoint Sensitivity: Traditional cognitive measures, while standard, may not be sufficiently sensitive or comprehensive to capture the nuanced, yet clinically meaningful, improvements in a heterogeneous AS population. The literature points to the ongoing development and validation of AS-specific tools, such as the Observer-Reported Communication Ability (ORCA) measure, which has demonstrated strong construct validity and established meaningful score differences, potentially offering a more relevant assessment of therapeutic impact.

• Disease Heterogeneity: The broad spectrum of symptoms and varying genotypes within AS make it challenging for a single intervention to demonstrate broad efficacy across all patients.

For Ultragenyx, this result necessitates a significant strategic pivot. The company plans to implement substantial expense reductions and re-focus on its growing commercial business, including new revenue from GENGLYCOS and the potential approval of UX111, aiming for profitability by 2027. This move reflects the high-risk, high-reward landscape of rare disease drug development, where pipeline setbacks can trigger immediate corporate restructuring.

Despite this particular outcome, the pursuit of disease-modifying therapies for AS continues. Other ASO candidates and gene replacement strategies are still advancing through clinical development, suggesting that the underlying scientific approach of targeting UBE3A may still hold promise. The path forward will likely involve a deeper understanding of patient stratification, refined trial designs, and the continued validation of more precise and sensitive outcome measures that truly reflect meaningful change for individuals living with Angelman syndrome.